back-office Open An Account
partner-with-us Partner with Us
Corporate Actions
Wockhardt jumps 21% in two days on US FDA nod for Zaynich NDA

02-Dec-25   14:44 Hrs IST
The stock has now surged 21.47% over two days, powered by the US FDA's acceptance of its New Drug Application (NDA) for the breakthrough antibiotic Zaynich.

The approval marks a landmark moment as it is the first time an Indian pharmaceutical company has had an NDA for a completely new chemical entity accepted by the US regulator. Zaynich, built on a novel β-lactam enhancer mechanism, has also received Fast Track status for its potential to address urgent medical needs. With over a decade of research behind it, the drug has demonstrated strong efficacy against highly resistant Gram-negative pathogens and has already helped critically ill patients in India and the US through compassionate use. The acceptance reflects confidence in Wockhardt's scientific depth and its global-standard development program.

Wockhardt is a global pharmaceutical and biotechnology company focused on developing innovative anti-infective solutions. The company posted a consolidated net profit of Rs 78 crore in Q2 FY26 compared with a net loss of Rs 22 crore a year earlier, while net sales declined 3.34% YoY to Rs 782 crore.

Powered by Capital Market - Live News

Attention Investors: Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.|| KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.|| No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.